Tandem Diabetes Care, Inc. (TNDM) Dividend History

Company News

• Infusion Devices Market to Reach US$ 23.08 Billion by 2031, Driven by Rising Prevalence of Infectious Diseases

  The global infusion devices market is expected to grow significantly due to the increasing prevalence of cancer and strategic initiatives by market players, reaching $23.08 billion by 2031.

  GlobeNewswire Inc.

  Featured Companies: BAX BDX ICUI MDT
• Why Tandem Diabetes Care Stock Thrashed the Market Today

  Tandem Diabetes Care received approval from the European Union's European Medicines Agency to use its t:slim X2 automated insulin delivery pump with Eli Lilly's Lyumjev ultra-rapid acting insulin. This is a positive development for both companies as they plan to expand the compatibility to other markets.

  The Motley Fool

  Featured Companies: LLY
• Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings? - Zacks Investment Research

  Boston Scientific Corporation is scheduled to report its Q2 2024 results on July 24. The company is expected to report revenue growth of around 11.7% and adjusted earnings of 58 cents per share. However, the company may face challenges from a challenging supply environment, rising costs, and healthcare staffing shortages.

  Zacks Investment Research

  Featured Companies: BSX EYE GKOS
• Critical Insights From Tandem Diabetes Care Analyst Ratings: What You Need To Know

  In the latest quarter, 15 analysts provided ratings for Tandem Diabetes Care (NASDAQ:TNDM), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 6 3 0 0 Last 30D 0 1 0 0 0 1M Ago 4 0 0 0 0 2M Ago 1 5 1 0 0 3M Ago 1 0 2 0 0 Analysts have recently evaluated Tandem Diabetes Care and provided 12-month price targets. The average target is $48.8, accompanied by a high estimate of $75.00 and a low estimate of $31.00. Witnessing a positive shift, the current average has risen by 33.7% from the previous average price target of $36.50. Analyzing Analyst Ratings: A Detailed Breakdown The standing of Tandem Diabetes Care among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Steven Lichtman Oppenheimer Raises Outperform $58.00 $47.00 Issie Kirby Redburn Atlantic Announces Buy $60.00 - Brooks O'Neil Lake Street Raises Buy $75.00 $60.00 Joanne Wuensch Citigroup Raises Buy $57.00 $40.00 Mathew Blackman Stifel Raises Buy $55.00 $45.00 Matt Miksic Barclays Raises Overweight $55.00 $39.00 Larry Biegelsen Wells Fargo Raises Overweight $50.00 $45.00 Matt O'Brien Piper Sandler Raises Overweight $50.00 $35.00 Jeff Johnson Baird Raises Neutral $36.00 $28.00 Larry Biegelsen Wells Fargo Raises Overweight $45.00 $21.00 Mike Kratky Leerink Partners Raises Outperform $45.00 $34.00 Mathew Blackman Stifel Raises Buy $40.00 $37.00 Joanne Wuensch Citigroup Raises Neutral $38.00 $31.00 Mathew Blackman Stifel Raises Buy $37.00 $24.00 Joanne Wuensch Citigroup Raises Neutral $31.00 $25.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. ...Full story available on Benzinga.com

  Benzinga
• Abbott Labs’ fourth-quarter sales top estimates amid strong medical-device demand

  Abbott Laboratories on Wednesday reported fourth-quarter sales that topped expectations amid strength in its medical-device and nutrition segments.

  MarketWatch

  Featured Companies: ABT LLY